Amiodarone
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Gilteritinib
FLT3 tyrosine kinase inhibitor (antineoplastic) · Unknown
Also known as Xospata
START
120 mg PO once daily; ECG/LFT/lipase baseline
TYPICAL MAX
120 mg/day
STOP IF
Differentiation syndrome, PRES, severe pancreatitis, or QTc >500 ms
WATCH
ECG/QTc, LFTs, lipase, fever/dyspnoea (diff syndrome), neuro
CDSCO approvedATC L01EX13
KDIGO 2024 + manufacturer label
- ONSET
- 2h · absorption
- PEAK
- 5h · Tmax
- t½
- 4.7d · t½ ~5 d
- DURATION
- 1d · once-daily
EXCRETION
Mainly faecal (~65%); ~17% renal
route + CYP
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Can cause fetal harm — avoid; effective contraception during and 2 months after.
FDA category + note
Top interactionssee all 12 →
- AmiodaroneSevereDatabaseDDInter
- AmisulprideSevereDatabaseDDInter
- AmprenavirSevereDatabaseDDInter
- AnagrelideSevereDatabaseDDInter
Mechanism
Selective FLT3 (both ITD and TKD mutants) and AXL kinase inhibitor, blocking proliferation/survival signalling in FLT3-mutated AML.
Indications
Relapsed/refractory FLT3-mutated acute myeloid leukaemia (R/R FLT3+ AML)
Dosing
- Adult
- 120 mg PO once daily (with or without food); response usually requires ≥4 weeks; reduce for toxicity.
- Pediatric
- Not established.
- Renal adjustment
- No adjustment for mild–moderate; severe (eGFR <30): not studied.
- Hepatic adjustment
- Mild: no adjustment; moderate–severe: not studied — caution.
- Geriatric
- No specific adjustment; monitor closely.
- Max dose
- 120 mg/day
Pharmacokinetics
Onset
Antileukaemic effect over weeks
Peak effect
~4–6 h (Tmax)
Duration
~24 h (once-daily)
Half-life
~113 h (~4.7 days)
Bioavailability
Not significantly food-affected
Protein binding
~94%
Metabolism
Hepatic CYP3A4 (primary); P-gp/BCRP substrate
Excretion
Mainly faecal (~65%); ~17% renal
Contraindications
- Severe hypersensitivity
- Caution: QT prolongation, posterior reversible encephalopathy history, pancreatitis
Side effects
Common
Transaminase elevationMyalgiaFatiguePyrexiaDiarrhoeaHypotension
Serious
- Differentiation syndrome (boxed)
- Posterior reversible encephalopathy (PRES, boxed)
- QT prolongation
- Pancreatitis
- Pulmonary toxicity / ARDS
Pregnancy & lactation
Pregnancy
Can cause fetal harm — avoid; effective contraception during and 2 months after.
Lactation
Avoid breastfeeding during and 2 months after therapy.
Drug interactions
Amisulpride
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Amprenavir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Anagrelide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Apalutamide
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Arsenic Trioxide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Atazanavir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Bedaquiline
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Bepridil
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Bexarotene
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Boceprevir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Cabozantinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Related guidelines
Ask House about Gilteritinib
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e, Katzung, BNF·Verified: 2026-05-20 · House clinical team·Cockpit curated: 2026-05-20